Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Gain Therapeutics, Inc.GANX · Entity 6943 | See Remark | March 24, 2026 | March 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Gain Therapeutics, Inc.
Report date March 24, 2026 · Filed March 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2036-03-24 | Direct | 50,000 |
Reported balance
After 2026-03-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-24 · Grant · Acquired 50,000 · Balance 50,000 F1: The shares underlying the option shall vest 25% on March 24, 2027, and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option shall vest 25% on March 24, 2027, and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 24, 2026 Filed Mar 27, 2026 00:00 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001104659-26-035400 · tm269848-1_4seq1.xml · derivative · entry 1 Fuggetta Gianluca · CIK 0001958188 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-03-24 F1 · derivative.exercise_date: The shares underlying the option shall vest 25% on March 24, 2027, and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| March 20, 2025 Filed Mar 22, 2025 00:00 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001493152-25-011179 · ownership.xml · derivative · entry 1 Fuggetta Gianluca · CIK 0001958188 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-03-20 F1 · derivative.exercise_date: The shares underlying the option shall vest 25% on March 20, 2026, and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 01:30 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0001493152-24-011216 · ownership.xml · derivative · entry 1 Fuggetta Gianluca · CIK 0001958188 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-03-21 F1 · derivative.exercise_date: The shares underlying the option shall vest 25% on March 21, 2025 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 21:27 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.84 | $0.00 |
DisclosureSEC source: 0001209191-23-021258 · doc4.xml · derivative · entry 1 Fuggetta Gianluca · CIK 0001958188 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-03-23 F1 · derivative.exercise_date: The shares underlying the option shall vest 25% on March 23, 2024 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.